[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1037500, "exercisedValue": 0, "unexercisedValue": 9922011}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 58, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tighe M. Reardon C.F.A., CPA", "age": 47, "title": "Acting Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 38.11, "open": 38.17, "dayLow": 37.1367, "dayHigh": 40.77, "regularMarketPreviousClose": 38.11, "regularMarketOpen": 38.17, "regularMarketDayLow": 37.1367, "regularMarketDayHigh": 40.77, "beta": 3.57, "forwardPE": -26.427631, "volume": 1075017, "regularMarketVolume": 1075017, "averageVolume": 718282, "averageVolume10days": 612920, "averageDailyVolume10Day": 612920, "bid": 40.1, "ask": 40.42, "bidSize": 200, "askSize": 100, "marketCap": 2095447808, "fiftyTwoWeekLow": 5.65, "fiftyTwoWeekHigh": 65.6, "priceToSalesTrailing12Months": 138.52368, "fiftyDayAverage": 41.5758, "twoHundredDayAverage": 29.938475, "currency": "USD", "enterpriseValue": 1472883200, "profitMargins": -2.91168, "floatShares": 25761353, "sharesOutstanding": 52164500, "sharesShort": 3663764, "sharesShortPriorMonth": 3574134, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.070199996, "heldPercentInsiders": 0.09418, "heldPercentInstitutions": 0.95677, "shortRatio": 6.58, "shortPercentOfFloat": 0.1388, "impliedSharesOutstanding": 52164500, "bookValue": 12.608, "priceToBook": 3.1860723, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -44045000, "trailingEps": -0.88, "forwardEps": -1.52, "pegRatio": -0.25, "enterpriseToRevenue": 97.368, "enterpriseToEbitda": -23.063, "52WeekChange": 2.6156616, "SandP52WeekChange": 0.24822903, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "JANX", "underlyingSymbol": "JANX", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "firstTradeDateEpochUtc": 1623418200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3a638123-d3da-3133-96c7-e6e8cabf84b3", "messageBoardId": "finmb_676965261", "gmtOffSetMilliseconds": -14400000, "currentPrice": 40.17, "targetHighPrice": 100.0, "targetLowPrice": 42.0, "targetMeanPrice": 67.14, "targetMedianPrice": 63.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 646292992, "totalCashPerShare": 12.39, "ebitda": -63864000, "totalDebt": 23820000, "quickRatio": 57.025, "currentRatio": 57.336, "totalRevenue": 15127000, "debtToEquity": 3.622, "revenuePerShare": 0.309, "returnOnAssets": -0.07979, "returnOnEquity": -0.09203, "freeCashflow": -36217124, "operatingCashflow": -46468000, "revenueGrowth": 7.417, "grossMargins": -2.51035, "operatingMargins": -1.55356, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]